Clinical research characterizing the mechanisms responsible for sex-based outcome differences postinjury remain conflicting. We sought to characterize an X chromosome-linked IRAK-1 (IL-1 receptor-associated kinase) polymorphism as an alternative mechanism responsible for sex differences postinjury. IRAK-1 is key intermediate in the toll-like receptor (TLR) pathway thought to drive inflammation postinjury. Methods: A prospective cohort study was performed over a 24-month period. Bluntly injured patients requiring intensive care unit admission were enrolled, whereas patients with isolated brain and spinal cord injuries were excluded. Outcomes of interest included multiple organ failure (MOF, Marshall MOD score > 5) and mortality. Logistic regression was utilized to determine the independent risk of poor outcome associated with the IRAK-1 variant after controlling for important differences. Results: In an enrolled cohort of 321 patients, the IRAK-1 variant was common (12.5%). Patients with and without the variant were similar in age, injury severity, and 24hr blood transfusion. After controlling for important confounders, the IRAK1 variant was independently associated with more than eightfold (OR = 8.4, P = 0.005, 95% CI: 1.9-37.1) and 11-fold (OR = 11.8, P = 0.037, 95% CI: 1.1-121) greater risk of MOF and mortality, respectively. These differences were most prominent in men, whereas women heterozygous for the variant demonstrated worse outcome in a dose-dependent fashion. Conclusions: The IRAK1 polymorphism is a strong independent predictor of MOF and mortality postinjury and represents a common variant with prognostic potential. These data demonstrate the importance of TLR signaling postinjury and supports that a genetic mechanism may drive sex outcome differences postinjury. (Ann Surg 2014;260:698-705) A lthough significant advances in the care of the injured patient have occurred over the last decade, those who survive their initial injury continue to be plagued with the development of coagulopathy, multiple organ failure (MOF), nosocomial infection (NI), and their attributable morbid effects. 1-6 A persistent finding has been that men and women respond differently after traumatic injury with significant Clearly, the background of others in our group, including Dr Vodovotz and Dr Billiar, really would suggest that the cytokine and chemokine relationships are much more complex than the absolute measurements. They are looking at these in the context of trends and as part of dynamic Bayesian networks and looking at it that way may reveal a more rigorous relationship or causal relationship, or associations at the very least, with outcomes.
protection afforded to the female sex. 7, 8 Controversy exists regarding the clinical explanation and underlying mechanisms responsible for this female protective effect. 7, 9, 10 A large body of laboratory evidence suggests that a sexhormone-based mechanism (estrogen being protective) is responsible for these postinjury differences. 8, [11] [12] [13] [14] In prior work, our group has shown that the protective effect afforded to women following severe injury is independent of age and the hormonal status of the female, suggesting other mechanisms may be involved clinically. 7, 15 Men and women also are different genetically, primarily due to the method of inheritance of, and the genes which reside on, the X chromosome. Secondary to the known mosaic expression of the X chromosome, women would be less affected by unfavorable X chromosome-linked genetic variants. 16 Importantly, increasing evidence also has demonstrated that the Toll-like receptor (TLR) signaling cascade plays an essential role in the early activation of the innate immune response after traumatic injury. [17] [18] [19] [20] [21] [22] [23] [24] The IL-1 receptor-associated kinase (IRAK-1) is a protein constituent member of the TLR signaling cascade, which resides on the X chromosome and has been demonstrated to have 2 haplotypes. The IRAK-1 variant haplotype has been demonstrated to be relatively common and associated with worse outcome in septic patients, thought to be secondary to an excessive innate immune response brought about by upregulated NF-κB signaling. [25] [26] [27] No evidence currently exists regarding the significance of this TLR pathway variant, which resides on the X chromosome on pertinent outcomes after traumatic injury. We sought to characterize the IRAK-1 variant as an alternative mechanism responsible for sex-based outcome differences postinjury. We hypothesized that the IRAK-1 variant would be common and independently associated with poor clinical outcome after traumatic injury.
METHODS
A prospective observational cohort study was performed over a 24-month time period (2011-2012) with the overarching goal to further characterize the mechanisms responsible for sex (male vs female) based outcome differences after traumatic injury. Inclusion criteria for the study included blunt injured patients older than 17 years requiring ICU (intensive care unit) admission. Patients older than 90 years, with isolated traumatic brain injury, preexisting immune-suppression, or those with an anticipated survival of less than 24 hours were excluded from enrollment. Blood samples were obtained within 6 hours of injury for serial cytokine measurements, coagulation assessment [international normalized ratio (INR), thromboelastography (TEG) analysis], and DNA isolation and haplotype discrimination. Clinical outcomes assessed included the development of MOF, NI, and mortality.
The IRAK-1 variant haplotype was determined by genotyping the single nucleotide polymorphism on the X chromosome where a T→ C substitution [rs1059703] at position 1595 in exon12 results in a nonsynonymous mutation (532, L→ S). Probe and primer combinations were designed for genotyping this polymorphism and polymerase chain reaction (PCR) was performed using an Applied Biosystems 7300 Real-Time PCR system using methods previously described. 25, 27 Allelic discrimination was verified by direct DNA sequencing of a small subgroup of patients of each haplotype (men and women: wild-type, variant, and heterozygous, respectively) to assure the PCR-based assay was sufficiently accurate.
MOF was evaluated using the well-validated Marshall Multiple Organ Dysfunction Score. 5, 28, 29 A Marshall Multiple Organ Dysfunction Score of more than 5 beyond 48 hours of injury and ICU admission was classified as MOF. Primary infectious outcomes of interest include ventilator-associated pneumonia, blood stream infection (excluding those associated with an intra-abdominal abscess), and urinary tract infections. 30 These were selected in attempts to use those infectious outcomes that can be used as a marker for the degree of relative immune suppression. The development of these NIs was based on positive culture evidence.
Blood samples were serially obtained at 6 hours, 24 hours, and 72 hours of injury, and serum was separated and frozen at −80 • C until assayed for cytokine analysis. Cytokine expression including IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IFN-α, and IFN-γ were measured from patients' serum using a Luminex 100 IS System and commercially available human specific beadsets. Thromboelastography (TEG) was performed within the first 6 hours of injury and at 24 hours using on a TEG 5000 Thromboelastograph Hemostasis Analyzer and standard TEG parameters were recorded including r value, k time, α angle, maximal amplitude (MA), G value, and fibrinolysis at 30 minutes (LY30) as previously described. [31] [32] [33] [34] [35] First, patients with and without the IRAK-1 polymorphism underwent unadjusted comparison of demographics, injury characteristics, resuscitation and transfusion requirements, and clinical outcomes. Multivariable logistic regression analysis was then utilized to determine the independent risks of our clinical outcomes associated with the IRAK-1 variant. Covariates adjusted for in the regression model included age, sex (male vs female), race, body mass index (BMI), injury severity score (ISS), presenting systolic blood pressure (SBP), presenting Glasgow Coma Score (GCS), intubation status, presenting coagulopathy (INR > 1.5), 24-hour crystalloid, and blood component transfusion requirements. Because of the X chromosome location of the polymorphism, we then characterized the risk of our clinical outcomes across whether the IRAK-1 variant existed in a homozygous manner (male-1 variant allele, female -2 variant alleles) or heterozygous manner (women-1 variant allele) to determine if a dose-response relationship existed. Finally, we characterized serial cytokine expression and TEG parameters for patients with and without the IRAK-1 polymorphism.
All data were summarized as mean ± SD, median (interquartile range), or percentage (%). Student t test or Mann-Whitney statistical test was used to compare continuous variables, whereas χ 2 test or Fischer exact test was used for categorical variables. P≤ 0.05 was considered statistically significant. The institutional review board at the University of Pittsburgh approved this study.
RESULTS
Over the study time period, 321 patients met inclusion and exclusion criteria and constituted the study cohort. The overall study cohort had a mean age of 50 ± 16 years, 70% male, and a median ISS of 16 [10, 21] . The cohort had an average ICU length of stay of 5.3 ± 6 days, and an overall incidence of MOF, NI, and mortality for the cohort was 8.1%, 27.0%, and 4.4%, respectively. The prevalence of the IRAK-1 polymorphism across men and women in the study cohort was 21.5% when heterozygous women (n = 29) were also included. For the purposes of the principal analyses, only homozygous patients (men-1 variant allele, women-2 variant alleles) were considered to have the IRAK-1 variant (12.5%). In the IRAK-1 variant group, 5 patients were female and were homozygous for the variant allele.
When IRAK-1 variant patients were compared with those with the normal haplotype, patients were similar in demographics, presenting vital and GCS, overall injury severity, and 24-hour resuscitation and transfusion requirements. (Table 1) . IRAK-1 patients were more commonly male and had a significantly higher rate of MOF and mortality in unadjusted comparison. Our logistic regression model was an excellent predictor of mortality with an area under the curve of 0.94 via receiver operating characteristic curve analysis. The model was also a strong predictor of MOF and adequate predictor of NI with area under the curve of 0.90 and 0.70, respectively. After controlling for all important confounders, the IRAK-1 variant was not a significant independent risk factor for the development of NI (OR = 1.6, P = 0.315, 95% CI: 0.62-4.3). When both MOF and mortality were analyzed, the IRAK-1 variant was significantly associated with over an eightfold greater independent odds of MOF (OR = 8.4, P = 0.005, 95% CI: 1.9-37.1) and over an 11-fold greater independent odds of mortality (OR = 11.8, P = 0.037, 95% CI: 1.1-121) ( Fig. 1) .
To characterize significance of homozygous or heterozygous status of the IRAK-1 variant, we first looked at the incidence of MOF and mortality across the haplotype designation ( Table 2 ). This unadjusted comparison revealed a dose-response relationship with heterozygous women having an intermediate incidence of MOF and mortality relative to the normal haplotype and homozygous IRAK-1 variant. When the haplotype (CT and CC relative to the normal haplotype TT) of the IRAK-1 variant was analyzed concurrently in the regression model, as compared to the odds of poor outcome associated with the normal haplotype, both the heterozygous haplotype and homozygous IRAK-1 variant were significant independent risk factors for MOF (P's 0.012 and 0.003, respectively). Only the homozygous IRAK-1 variant (CC) remained a significant independent risk factor for mortality when both variant haplotypes were included in the model. When serial cytokine measurements were characterized, early IL-6 and IL-10 levels were significantly correlated in a positive direction with the propensity to develop MOF and mortality; however, there was no significant relationship with serial cytokine expression and the IRAK-1 variant or IRAK-1 haplotype (TT, CT, CC).
When coagulopathy was further characterized, we first excluded those patients who presented on oral anticoagulation or antiplatelet medications (n = 91). We then looked the continuous TEG parameter variables and the extreme quartile (>75th percentile or < 25th percentile) associated with coagulopathy for each TEG parameter (r value, k time, α-angle, MA, G value, and LY30). When these were compared across TEG measurements drawn in the first 6 hours from injury, there were no significant differences found across those with and without the IRAK-1 variant. When TEG measurements that were performed at 24 hours out from injury were analyzed, there were significantly higher k time, α-angle, MA, and G values (P = 0.029, P = 0.021, P = 0.45, P = 0.043, respectively) in those patients with the IRAK-1 variant. As this represents a potential evolving coagulopathy over the initial 24 hours postinjury, we verified these significant differences in a regression model, which also controlled for differences in demographics, injury severity, and 24-hour resuscitation and transfusion requirements (age, sex, ISS, 24-hour blood, plasma, platelet, and crystalloid). After controlling for important differences across the groups, the IRAK-1 variant remained significantly associated in 3 out of the 4 TEG parameters with more than a threefold greater independent risk of coagulopathic tendency (α-angle, P = 0.018; MA, P = 0.047; and G value, P = 0.012, Fig. 2 ).
DISCUSSION
As few effective interventions exist, which alter the morbidity and mortality that inherently follows traumatic injury, investigation into novel mechanisms, which result in a protective effect may provide a route to reduce these sequelae postinjury. The ultimate elucidation of the mechanisms responsible for sex-based outcome differences will provide insight and understanding of novel therapeutic targets, which have significant potential to improve outcomes in both men and women postinjury.
TLRs are an evolutionarily conserved family of protein receptors, which are central to NF-κB cellular signaling and the initiation of the innate immune response to infection. [36] [37] [38] Accumulating evidence suggests that TLRs also recognize endogenous ligands that arise from cellular damage that are unrelated to infection. [21] [22] [23] [24] Compelling evidence has revealed that the TLR receptor, specifically TLR4, is required and plays a critical role in the early activation and upregulation of the innate immune response, the resultant systemic inflammatory response, and the secondary organ dysfunction, which is known to complicate and follow traumatic injury. [17] [18] [19] [20] Concurrently, it is known that women would potentially be less affected by an unfavorable X chromosome-linked genetic polymorphism due to the mosaic expression pattern of the X chromosome, which has been shown in other disease processes to be protective for women. 16, [39] [40] [41] The results of the current prospective analysis suggest that an IRAK-1 polymorphism, which is a TLR signaling pathway constituent that also resides on the X chromosome that is known to result in increased NF-κB cellular signalling, is strongly associated with the development of MOF and mortality in a prospectively enrolled cohort of injured patients that required ICU admission. Further confirmation of the significance of these findings is demonstrated by prevalence of the polymorphism in a single-center injured population and the doseresponse relationship determined by the haplotype (heterozygous or homozygous expression) of the IRAK-1 variant. The current results verify that the IRAK-1 polymorphism represents a common variant with prognostic potential and demonstrates the importance of TLR signaling postinjury and further supports that a genetic mechanism may in part drive sex-based outcome differences postinjury. These results compliment prior studies demonstrating a detrimental association of the IRAK-1 variant in patients with sepsis. 25, 26 Arcaroli and colleagues studied the same polymorphism to identify the IRAK-1 variant haplotype and characterized its association with clinical outcomes in a septic population (n = 155). The IRAK-1 variant was relatively common in this septic population (prevalence = 21.3%) and was associated with increased nuclear translocation of NF-κB (synonymous with NF-κB activation), more severe organ dysfunction, and independently associated with a higher risk of mortality, in this cohort of patients. Similarly, evidence exists that racial disparities exist in the strength of sex-based outcome differences, which correlates with the known prevalence of the IRAK-1 variant across different racial groups. 42 Importantly, the current results are not simply an extension of sex-based outcomes, which have been previously demonstrated after traumatic injury in multiple studies. 7, 15, [43] [44] [45] [46] [47] [48] [49] [50] [51] In the current 321 patient cohort, there were no significant differences in the clinical outcomes (NI, MOF, or mortality) across male and female sex nor was sex a significant covariate in any of the regression models. Prior studies demonstrating sex-based outcome differences postinjury have utilized larger retrospective and prospective injured populations and have demonstrated a significantly lower magnitude of risks of poor outcome across men and women with few able to characterize the risk of MOF and attributable complications. 7, [43] [44] [45] [46] [47] [48] [49] [50] [51] The strength of the current findings, demonstrated in a relatively small cohort of patients, provides insight into the magnitude of effect the IRAK-1 variant may have on clinical outcomes postinjury. Despite the strength of these clinical outcome findings, the underlying mechanism responsible remains less clearly characterized.
It is somewhat surprising that no differences in serial cytokine expression between patients with and without the IRAK-1 variant were found. It is known that IL-6 levels are a strong predictor of the development of MOF 52, 53 and despite the strong association between the IRAK-1 variant and MOF, no differences were found for IL-6 or other cytokine expression. Importantly, the full spectrum of circulating mediators that might contribute to the immune response driven by TLR and IRAK-1 were not able to be measured for the analysis. The most current paradigm holds that increased innate immune activity leads to proinflammatory mediators and subsequent organ dysfunction and attributable morbidity and mortality. 54 The lack of any significant measurable differences in the proteomic (cytokine) response may call into question this paradigm in this particular circumstance. It may be that either early proteomic or innate immune response differences exist but were not able to be appropriately measured by standard cytokine analysis which was undertaken, or that the clinical outcome differences found follow an alternative paradigm or model in this specific situation.
We attempted to characterize the early and evolving coagulopathy for the cohort as it has been shown to be a significant risk factor for poor outcome and we have previously demonstrated significant differences in the risk of coagulopathy across male and female sex postinjury. [55] [56] [57] [58] [59] [60] Although no TEG parameter differences were demonstrated early (6 hours) postinjury, a strong relationship with evolving coagulopathy over the first 24 hours was demonstrated. It may be that patients at high risk for MOF have a tendency toward coagulopathy or these early differences in coagulation may be in part driving the risk of MOF. Mechanistic possibilities include that the TLR signaling cascade by way of the IRAK-1 polymorphism in some way drives this evolving coagulopathy. It has been previously demonstrated that hypoperfusion and activated protein C are principal drivers of traumainduced coagulopathy. 61, 62 Importantly, hemorrhagic shock and traumatic injury are principal drivers of TLR activation. 63, 64 It may be that the principal drivers of these occurrences overlap. Importantly, there were no significant differences in the initial 24-hour transfusion or resuscitation requirements across patients with and without the IRAK-1 variant. The TEG parameters, which were found to be significantly abnormal after adjustment, were the α-angle, MA, and G value. The α-angle characterizes the rate of thrombin generation; conversion of fibrinogen to fibrin; and the interactions among fibrinogen, fibrin, and platelets. Both the MA and G value TEG parameters characterize the overall clot strength with contributors to clot strength including platelet and fibrinogen function. The current results verify there is an association with the IRAK-1 variant in this cohort with evolving coagulopathy based on serial TEG measurements. However, the current analysis is unable to provide causal information regarding these developments and the interaction of MOF, coagulopathy, and the early innate immune response postinjury.
The current analysis does have several limitations that deserve discussion. First, this study was performed at a single, level I trauma center and may not be generalizable or pertinent to other centers with differing admission demographics, injury characteristics, or management practices. Although the data collected for the prospective cohort analysis was extensive, potential unknown or unmeasured confounding variables may be responsible for the associations described and the conclusions formulated. The study group represents a smaller cohort than previous sex studies but is substantially larger than some of the prior sepsis studies for which the IRAK-1 variant has been characterized clinically. 15, 25 There was a lower than expected incidence of the Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
selected pertinent outcomes of the study including MOF and mortality, which can have an exaggeratory effect on the odds ratios presented in certain circumstances. Importantly, it has been previously demonstrated that a large portion of the most critically injured patients suffer mortality relatively early, commonly within the first 48 hours. 65 Because of the requirement of informed consent, the most critically ill patients had a lower consent rate significantly reducing the incidence of mortality for the study cohort. Although the within 6-hour early cytokine expression measurements that were performed represent a relatively early time point compared with most other studies, this may still represent a delayed measurement for cytokine expression, which drives the development of MOF and mortality. Finally, our current understanding of the early coagulopathy, which complicates trauma, is just beginning to expand because of the complex nature of the process. The most appropriate analysis of TEG parameters remains controversial with variability in the methods of comparison across studies. [31] [32] [33] [34] [35] We utilized the extreme quartile, either more than 75% or less than 25% depending on the specific parameter for logistic regression modeling. This possibly may result in an underestimation or overestimation of coagulopathic tendency for specific patients.
CONCLUSIONS
The IRAK-1 polymorphism is a strong independent predictor of MOF and mortality postinjury and represents a common variant with prognostic potential. These data demonstrate the importance of TLR signaling postinjury and supports that an X -chromosomelinked genetic mechanism may drive sex-based outcome differences postinjury.
It's not often that you discuss a paper that may change an entire paradigm of how we approach a disease. I believe this paper has that potential.
One of the holy grails of trauma care is elucidating why 2 similar people hit by the same truck with identical injuries have different outcomes. One of the major differences identified over the last decades is that women and men behave differently to identical injuries.
However, we have failed to fully explain why. As you heard, hormonal differences were the obvious cause invoked initially and confirmed in models. But, in the human setting, the mice results do not hold up. The obvious conclusion is that women are stronger than men and are better able to tolerate severe injury. Today, the authors further provide a unique insight of a potential genetic basis for this observed gender bias in outcome, and, in part, explain why previous studies focused on a proteomic gender difference, primarily hormonal, have not been reproducible.
The authors focus on the IRAK gene, and its polymorphisms as an X chromosome-linked gene. Men, as described, are much more likely to express any polymorphism, and express it homozygously, compared to the double-X chromosome female. In their study, they were then able to show their individuals having a homozygous dysfunctional polymorphism had a markedly increased risk of MOF and mortality using multiple different analyses.
The analysis is very clean and very exciting. The data focus on the genetic cause of the difference rather than chasing genomic products, or proteomes, which we have done for decades and have failed. Attempts at modifying protein levels have not succeeded in improving survival.
I have 3 questions for the authors.
The current paradigm is based on the variable response in hormonal levels between men and women. The authors do not mention whether they measured hormonal levels in their various cohorts of IRAK polymorphisms. Is there a linkage between select hormonal expressions and polymorphism particularly in the heterozygous female? Is hormonal protein production variable based on these various cohorts?
Second, the authors similarly demonstrate that, while IRAK is known to control inflammatory mediator production, they were unable to discern any differences in inflammatory mediator levels between the various polymorphism cohorts. Do they have an explanation? With the increased IRAK activation they demonstrate, there should have been a marked increase in proinflammatory mediators. Why were they unable to demonstrate any increase?
Is there another level of control that's more important than the gene? Is there evidence of increased inflammatory protein production that is not being released or is not being processed to a functional state?
The third question is an extension of this principle. The only functional assay examined was coagulation. Again, they demonstrate that coagulopathy was worse in patients with this genetic polymorphism variant. However, were they able to identify any of the recognized mediators of trauma-induced coagulopathy and whether the genetic polymorphism variant produced a difference in levels of those mediators? Was there any correlation between the genetic cohorts and the biology of coagulation?
Response From B. Zuckerbraun:
Thank you. It has been a privilege to present this work and represent our lead author, Dr Jason Sperry. In regard to associating the IRAK1 variant with differences in hormonal production, at the level of simple analysis we did not see any measurable differences of statistical significance between patients with the IRAK1 variant and those without, again suggesting that the mechanisms of action related to IRAK1 and innate immune signaling may extend beyond and be independent of hormone production.
Dr Sperry is looking intensely at the temporal relationship of hormones, including estrogens and testosterones, which may suggest that there is a difference that occurs over time and that the relationship may be quite complex, without relationship to the IRAK1 variant.
With regard to looking at our association of IRAK1 variant and the cytokine response, we were a bit surprised when we did not see a difference, especially knowing that cytokines, such as IL-6, have been clearly shown to be associated with outcomes such as MOF. But as you mentioned, perhaps we shouldn't be so surprised for a number of reasons. The complexity of cytokines or chemokine measurements or other inflammatory mediators extends beyond that of simple measurements of absolute values and may have more to do with trends. In addition, values of these parameters may change drastically depending on when they are measured, specifically in relationship to the timing of injury, in relationship to the timing of resuscitation efforts, so on and so forth, and, again, may suggest that overinterpretation of the importance of these inflammatory parameters on a causal association with MOF or poor outcome measurements is not accurate.
In relationship to trauma-induced coagulopathy, again, I think there's a little bit of an oversimplification of looking at this as a single phenotypic entity, and perhaps the coagulopathy that's seen early is very different than a coagulopathy that you may see at 24 hours, which, again, may be a manifestation of a measurement of overall immune dysfunction that is occurring at this time point. However, we have not looked specifically at any of the known factors associated with coagulopathy other than looking at the coagulopathy as determined by thromboelastography itself.
DISCUSSANTS

D. Soybel (Hershey, PA):
I think this type of work is important and thought-provoking. Along those lines, I wondered if you could clarify for us just a little bit about the biology of the IRAK1 variant. First of all, you mentioned it's a nonsynonymous variant. My question in that regard is, is this a deletion or is it an alteration of the receptor so that it is more or less responsive to interleukin 1?
Second, this IRAK1 variant, I believe, has also been associated with autoimmune diseases like lupus that are more likely to occur in women. So, I sort of wonder if there is some broader issue involved, such as susceptibility to persistent inflammation or nonresolving inflammation. If so, what your thoughts are about why it persists in the population if it's so maladaptive.
Response From B. Zuckerbraun:
The interesting thing about this IRAK1 variant is there are overall 8 polymorphisms seen in this variant. Invariably, almost all 8 are always seen in the presence of this variant. The one that we measured on this specific exon is just the one that's been described previously.
What that results in is definitely this hyper-exaggerated inflammatory response, which has been demonstrated in vitro. For example, increased NF-κB signaling has been measured as part of that exaggerated response. What the genetic variant does to the protein levels or function has been less clear. Whether or not that alters the phosphorylating ability of the kinase or perhaps alters the ubiquitination sites of the protein. But functionally, it is clear that the variant does phenotypically result in exaggerated downstream signaling.
In addition, pertaining to your second question, it seems to be expressed in a recessive fashion in some circumstances, which may predispose to some of the ongoing inheritance of this variant. As far as the variant's role in other inflammatory diseases that is an ongoing question. We highlighted the response in sepsis and the results of this manuscript illustrate in patients that are surviving their initial traumatic insults are experiencing complications, including mortality and organ dysfunction related to that immune dysfunction of trauma. So, this is clearly a gene variant that has been associated with genetic predisposition to susceptibility to inflammatory responses in the setting of infection or other immune-mediated diseases makes is all I can comment on.
May this variant be protective for other disease processes where that hyperexaggerated immune response be beneficial? For example, in some cancers. It is known that the polymorphism exists quite commonly in certain populations. For example, 80% of Chinese populations have the polymorphism. So, it remains to be seen.
DISCUSSANTS T. Buchman (Atlanta, GA):
I have a question as to the degree to which your analysis depends on the assumption that women who are heterozygous are expressing at 50%, if you will. Women are natural mosaics with regard to X chromosome inactivation. For example, as seen in the hair color of a calico cat or a tortoise shell cat, inactivation may not be 50% with respect to a given allele. There's a bell-shaped curve to it. Given the relatively small numbers in your study, I wonder about the extent to which your analysis might be affected by the heterozygotes whose X chromosomes are unevenly inactivated, that is they are at one end of the bell curve or the other.
Response From B. Zuckerbraun:
That's a great point, and we don't know the answer to that question.
T. Buchman (Atlanta, GA):
Did you consider doing a methylation analysis of a closely linked gene to see, in a given subject, whether the X chromosome inactivation pattern was even or distributed at one end of the curve or the other?
Response From B. Zuckerbraun:
We could do that; we have not. We had done our analysis excluding heterozygotes from each group. Regardless of that, there were still differences between the normal haplotypes and the homozygous patients. But you bring up a good point that heterozygotes represent perhaps a very mixed population along that spectrum, based on differences in mosaic expression to varying extents throughout the body.
DISCUSSANTS
A. Harken (Oakland, CA):
I'm sure you, in chasing the mechanism, were disappointed that the inflammatory cytokines did not correlate with the IRAK polymorphism, but I guess my questions is, I think of a hormone as being a small amount of material working at a distance and a cytokine as a sometimes relatively large amount of material working locally.
You guys have a huge amount of experience in this. Can you help us or me interpret how we should think of circulating cytokines, just measuring them and relating them to anything that's happening locally?
So, I think the real question is, can you apply that to clinical care? Can you perform these analyses, the measurements, and then the interpretation of these measurements to affect care real time? I think that will continue to be a challenge.
The beauty of the genetic variant is that although, again, there's still some challenge in measuring that in real time, but the genetic variant is not changed in relationship to the timing postinjury, so on and so forth. If it could be measured early, you could perhaps target that higher at-risk population early in the course of their care or down the road as this genetic predisposition is going to be omnipresent throughout their hospital stay and life.
